Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia

Trial Profile

A Phase II Study of Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2019

At a glance

  • Drugs Daratumumab (Primary) ; Ibrutinib (Primary)
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Jan 2019 Planned End Date changed from 1 Nov 2023 to 1 Mar 2024.
    • 03 Jan 2019 Planned primary completion date changed from 1 Nov 2021 to 1 Mar 2022.
    • 03 Jan 2019 Planned initiation date changed from 1 Nov 2018 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top